Platinum rechallenge in patients with advanced NSCLC: A pooled analysis

Lung Cancer

Volumn 81, Issue 3, 2013, Pages 337-342

  Petrelli, Fausto ^a   Coinu, Andrea ^a   Cabiddu, Mary ^a   Ghilardi, Mara ^a   Ardine, Mara ^a   Barni, Sandro ^a  

^a TREVIGLIO HOSPITAL   (Italy)

Author keywords

Metastatic; NSCLC; Platinum based doublets; Rechallenge; Second line

Indexed keywords

PEMETREXED; TAXANE DERIVATIVE;

ALOPECIA; ANEMIA; ASTHENIA; CANCER CHEMOTHERAPY; CANCER PATIENT; CHI SQUARE TEST; COMPUTER PROGRAM; DIARRHEA; FATIGUE; HUMAN; LUNG NON SMALL CELL CANCER; META ANALYSIS; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SURVIVAL TIME; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

METASTATIC; NSCLC; PLATINUM-BASED DOUBLETS; RECHALLENGE; SECOND LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; ODDS RATIO; PLATINUM; PUBLICATION BIAS; RETREATMENT; TREATMENT OUTCOME;

EID: 84881670161     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.06.022     Document Type: Review

References (26)

1. Shepherd F.A., Dancey J., Ramlau R., Mattson K., Gralla R., O'Rourke M., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000, 18:2095.
2. Fossella F.V., DeVore R., Kerr R.N., Crawford J., Natale R.R., Dunphy F., et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000, 18:2354.
3. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De Marinis F., von Pawel J., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22:1589.
4. Di Maio M., Chiodini P., Georgoulias V., Hatzidaki D., Takeda K., Wachters F.M., et al. Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2009, 27:1836.
5. Garassino M.C., Torri V., Michetti G., Lo Dico M., La Verde N., Aglione S., et al. Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis. Lung Cancer 2011, 72:378.
6. Cantù M.G., Buda A., Parma G., Rossi R., Floriani I., Bonazzi C., et al. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol 2002, 20:1232.
7. Qi W.X., Tang L.N., He A.N., Shen Z., Yao Y. Effectiveness and safety of pemetrexed-based doublet versus pemetrexed alone as second-line treatment for advanced non-small-cell lung cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol 2012, 138(May (5)):745-751.
8. Qi W.X., Shen Z., Yao Y. Meta-analysis of docetaxel-based doublet versus docetaxel alone as second-line treatment for advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 2012, 69(January (1)):99-106.
9. Ardizzoni A., Tiseo M., Boni L., Vincent A.D., Passalacqua R., Buti S., et al. Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase ii study and pooled analysis with the NVALT7 trial. J Clin Oncol 2012, 30(December (36)):4501-4507.
10. Pallis A.G., Agelaki S., Agelidou A., Varthalitis I., Syrigos K., Kentepozidis N., et al. A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic non-small cell lung cancer. BMC Cancer 2010, 10(November):633.
11. Metro G., Chiari R., Mare M., Giannarelli D., Tofanetti F.R., Minotti V., et al. Carboplatin plus pemetrexed for platinum-pretreated, advanced non-small cell lung cancer: a retrospective study with pharmacogenetic evaluation. Cancer Chemother Pharmacol 2011, 68(December (6)):1405-1412.
12. Kim H.S., Lee G.W., Kim J.H., Kim H.Y., Kwon J.H., Song H.H., et al. A phase II study of pemetrexed and carboplatin as a salvage therapy for platinum-pretreated patients with non-small cell lung cancer. Lung Cancer 2010, 70(October (1)):71-76.
13. Zhang G.Z., Jiao S.C., Meng Z.T. Pemetrexed plus cisplatin/carboplatin in previously treated locally advanced or metastatic non-small cell lung cancer patients. J Exp Clin Cancer Res 2010, 29(April):38.
14. Zhang Y.F., Chen Z.W., Lu S. Pemetrexed monotherapy versus pemetrexed plus platinum combination as second-line treatment for advanced non-small cell lung cancer. Chin Med J (Engl) 2009, 122(October (20)):2472-2476.
15. Arrieta O., Villarreal-Garza C., Pachuca D., Michel Ortega R.M., Martinez-Barrera L., Flores-Estrada D., et al. High response of second-line chemotherapy with pemetrexed or gemcitabine combined with carboplatin in patients with non-small-cell lung cancer experiencing progression following 6 months after concluding platinum-based chemotherapy. Med Oncol 2011, 28(March (1)):300-306.
16. Yoh K., Kubota K., Kakinuma R., Ohmatsu H., Goto K., Niho S., et al. Phase II trial of carboplatin and paclitaxel in non-small cell lung cancer patients previously treated with chemotherapy. Lung Cancer 2007, 58(October (1)):73-79.
17. Numico G., Colantonio I., Gasco M., Bertelli G., Garrone O., Occelli M., et al. Carboplatin and weekly paclitaxel in non-small cell lung cancer patients unfit for or pretreated with chemotherapy. Anticancer Res 2005, 25(May-June (3c)):2555-2559.
18. Seto T., Takezako Y., Nakamura H., Takeda K., Inoue F., Semba H., et al. Doublet regimen of cisplatin plus docetaxel for second-line chemotherapy after prior therapy with cisplatin plus irinotecan for non-small cell lung cancer: a phase II study. Int J Clin Oncol 2004, 9(October (5)):378-382.
19. Stathopoulos G.P., Rigatos S., Malamos N.A. Paclitaxel combined with cis-platin as second-line treatment in patients with advanced non-small cell lung cancers refractory to cis-platin. Oncol Rep 1999, 6(July-August (4)):797-800.
20. Smit E.F., Burgers S.A., Biesma B., Smit H.J., Eppinga P., Dingemans A.M., et al. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J Clin Oncol 2009, 27(April (12)):2038-2045.
21. Kaye S.B., Colombo N., Monk B.J., Tjulandin S., Kong B., Roy M., et al. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval. Ann Oncol 2011, 22(January (1)):49-58.
22. Scagliotti G., Hanna N., Fossella F., Sugarman K., Blatter J., Peterson P., et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009, 14:253.
23. de Boer R.H., Arrieta Ó., Yang C.H., Gottfried M., Chan V., Raats J., et al. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol 2011, 29(March (8)):1067-1074.
24. Herbst R.S., Sun Y., Eberhardt W.E., Germonpré P., Saijo N., Zhou C., et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 2010, 11(July (7)):619-626.
25. Qi W.X., Tang L.N., He A.N., Shen Z., Yao Y. The role of vandetanib in the second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of four randomized controlled trials. Lung 2011, 189(December (6)):437-443.
26. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353(July (2)):123-132.